181 related articles for article (PubMed ID: 2329455)
1. Problems of mass screening for neuroblastoma: analysis of false-negative cases.
Ishimoto K; Kiyokawa N; Fujita H; Yabuta K; Ohya T; Miyano T; Shinohara T; Sera Y
J Pediatr Surg; 1990 Apr; 25(4):398-401. PubMed ID: 2329455
[TBL] [Abstract][Full Text] [Related]
2. Mass screening for neuroblastoma: quo vadis? A 9-year experience from the Pediatric Oncology Study Group of the Kyushu area in Japan.
Suita S; Zaizen Y; Sera Y; Takamatsu H; Mizote H; Ohgami H; Kurosaki N; Ueda K; Tasaka H; Miyazaki S; Sugimoto T; Kawakami K; Tsuneyoshi M; Yano H; Akiyama H; Ikeda K
J Pediatr Surg; 1996 Apr; 31(4):555-8. PubMed ID: 8801312
[TBL] [Abstract][Full Text] [Related]
3. Different genomic and metabolic patterns between mass screening-positive and mass screening-negative later-presenting neuroblastomas.
Nakagawara A; Zaizen Y; Ikeda K; Suita S; Ohgami H; Nagahara N; Sera Y; Akiyama H; Kawakami K; Uchino J
Cancer; 1991 Nov; 68(9):2037-44. PubMed ID: 1913552
[TBL] [Abstract][Full Text] [Related]
4. Neuroblastoma detected by mass screening: the Tumor Board's role in its treatment.
Okazaki T; Kohno S; Mimaya J; Hasegawa S; Urushihara N; Yoshida A; Kawano S; Kusafuka J; Horikoshi Y; Takashima Y; Aoki K; Hamazaki M
Pediatr Surg Int; 2004 Jan; 20(1):27-32. PubMed ID: 14689211
[TBL] [Abstract][Full Text] [Related]
5. Chromosome findings and prognosis in 15 patients with neuroblastoma found by VMA mass screening.
Hayashi Y; Inaba T; Hanada R; Yamamoto K
J Pediatr; 1988 Apr; 112(4):567-71. PubMed ID: 3351679
[TBL] [Abstract][Full Text] [Related]
6. Problems of neuroblastoma screening for 6 month olds and results of second screening for 18 month olds.
Hayashi Y; Ohi R; Yaoita S; Nakamura M; Kikuchi Y; Konno T; Tsuchiya S; Shiraishi H
J Pediatr Surg; 1995 Mar; 30(3):467-70. PubMed ID: 7760244
[TBL] [Abstract][Full Text] [Related]
7. Outcome of infants with neuroblastoma detected by mass screening and surgically treated in Shiga Prefecture, Japan: what is the role of surgery?
Hase T; Ohta S; Tani T; Mizukuro T; Mekata E; Naitoh H; Shimadera S; Fujino S; Taga T
Pediatr Surg Int; 2002 Sep; 18(5-6):289-94. PubMed ID: 12415341
[TBL] [Abstract][Full Text] [Related]
8. Screening for neuroblastoma: a review of the evidence.
Chamberlain J
J Med Screen; 1994 Jul; 1(3):169-75. PubMed ID: 8790511
[TBL] [Abstract][Full Text] [Related]
9. [Amplification of the N-myc cellular oncogene in neuroblastoma. Relation to other tumor markers].
Verdona G; Garaventa A; Coviello DA; Cornaglia-Ferraris P; Tonini GP
Boll Ist Sieroter Milan; 1986; 65(4):304-8. PubMed ID: 3790277
[TBL] [Abstract][Full Text] [Related]
10. Centrosome amplification is correlated with ploidy divergence, but not with MYCN amplification, in neuroblastoma tumors.
Fukushi D; Watanabe N; Kasai F; Haruta M; Kikuchi A; Kikuta A; Kato K; Nakadate H; Tsunematsu Y; Kaneko Y
Cancer Genet Cytogenet; 2009 Jan; 188(1):32-41. PubMed ID: 19061778
[TBL] [Abstract][Full Text] [Related]
11. Screening for neuroblastoma in France: methodological aspects and preliminary observations.
Chauvin F; Mathieu P; Frappaz D; Lasset C; Favrot MC; Greffe J; Esteve J; Thiesse P; Combaret V; Chauvot P; Boschetti R; David L; Brunat-Mentigny M; Philip T
Med Pediatr Oncol; 1997 Feb; 28(2):81-91. PubMed ID: 8986143
[TBL] [Abstract][Full Text] [Related]
12. Current urinary mass screening for catecholamine metabolites at 6 months of age may be detecting only a small portion of high-risk neuroblastomas: a chromosome and N-myc amplification study.
Kaneko Y; Kanda N; Maseki N; Nakachi K; Takeda T; Okabe I; Sakurai M
J Clin Oncol; 1990 Dec; 8(12):2005-13. PubMed ID: 2230892
[TBL] [Abstract][Full Text] [Related]
13. Similar chromosomal patterns and lack of N-myc gene amplification in localized and IV-S stage neuroblastomas in infants.
Hayashi Y; Inaba T; Hanada R; Yamada M; Nakagome Y; Yamamoto K
Med Pediatr Oncol; 1989; 17(2):111-5. PubMed ID: 2704332
[TBL] [Abstract][Full Text] [Related]
14. N-myc amplification in neuroblastomas: histopathological, DNA ploidy, and clinical variables.
Oppedal BR; Oien O; Jahnsen T; Brandtzaeg P
J Clin Pathol; 1989 Nov; 42(11):1148-52. PubMed ID: 2584426
[TBL] [Abstract][Full Text] [Related]
15. N-myc oncogene and stage IV-S neuroblastoma. Preliminary observations on ten cases.
Nakagawara A; Sasazuki T; Akiyama H; Kawakami K; Kuwano A; Yokoyama T; Kume K
Cancer; 1990 May; 65(9):1960-7. PubMed ID: 2196987
[TBL] [Abstract][Full Text] [Related]
16. Fluctuation in the concentrations of vanillylmandelic acid and homovanillic acid in mass screening for neuroblastoma.
Nishi M; Miyake H; Takeda T; Yamashiro K; Takasugi N; Hanai J; Kawai T
Eur J Pediatr; 1990 Sep; 149(12):859-61. PubMed ID: 2226572
[TBL] [Abstract][Full Text] [Related]
17. Risks and benefits of ending of mass screening for neuroblastoma at 6 months of age in Japan.
Tajiri T; Souzaki R; Kinoshita Y; Tanaka S; Koga Y; Suminoe A; Matsuzaki A; Hara T; Taguchi T
J Pediatr Surg; 2009 Dec; 44(12):2253-7. PubMed ID: 20006005
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker chromosome 1.
Hayashi Y; Kanda N; Inaba T; Hanada R; Nagahara N; Muchi H; Yamamoto K
Cancer; 1989 Jan; 63(1):126-32. PubMed ID: 2910410
[TBL] [Abstract][Full Text] [Related]
19. Genetic clinical markers of human neuroblastoma with special reference to N-myc oncogene: amplified or not amplified?--An overview.
Tsuchida Y; Hemmi H; Inoue A; Obana K; Yang HW; Hayashi Y; Kanda N; Shimatake H
Tumour Biol; 1996; 17(2):65-74. PubMed ID: 8658015
[TBL] [Abstract][Full Text] [Related]
20. Neuroblastoma with N-myc amplification detected by urine: mass screening in infants after the sixth month of life.
Kerbl R; Urban C; Starz I; Ambros IM; Strehl S; Kovar H; Gadner H; Ambros PF
Med Pediatr Oncol; 1993; 21(9):625-6. PubMed ID: 8412992
[No Abstract] [Full Text] [Related]
[Next] [New Search]
